NovaXS Biotech

NovaXS Biotech

Early Stage

Needle-free self-injection technology | Ease of use, painless, better care

Needle-free self-injection technology | Ease of use, painless, better care

Overview

Raised to Date: Raised: $114,193

Total Commitments ($USD)

Platform

Republic

Start Date

12/05/2022

Close Date

02/02/2023

Min. Goal
$25,000
Max. Goal
$1,235,000
Min. Investment

$100

Security Type

SAFE

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$14,000,000

Discount

20%

Rolling Commitments ($USD)

Status
Funded
Reporting Date

02/27/2023

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$1,935

# of Investors

231

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2021

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

Medium

Capital Intensity

Low

Location

Trabuco Canyon, California

Business Type

Growth

NovaXS Biotech, with a valuation of $14 million, is raising funds on Republic. The company is developing needle-free self-injection technology for ease of use, painless drug delivery, and better care. NovaXS Biotech smart system aims to simplify the medication self-administration process and improve remote treatment outcomes with one simple click on the device. NovaXS Biotech has filed four patents to protect its technology, is finalizing prototypes, and targeting commercial launch in the second quarter of 2024. Alina Su, Jonathan Xing, and Alex You founded NovaXS Biotech in January 2021. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.24 million. The campaign proceeds will be used to initiate licensing, launch the product, and promote sales.

Summary Profit and Loss Statement

FY 2021 FY 2020

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-62,494

$0

Summary Balance Sheet

FY 2021 FY 2020

Cash

$297,216

$0

Accounts Receivable

$0

$0

Total Assets

$297,216

$0

Short-Term Debt

$7,872

$0

Long-Term Debt

$290,000

$0

Total Liabilities

$297,872

$0

Financials as of: 12/05/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
NovaXS Biotech on Republic 2022
Platform: Republic
Security Type: SAFE
Valuation: $14,000,000

Follow company

Follow NovaXS Biotech on Republic 2022

Buy NovaXS Biotech's Deal Report

Warning: according to the close date for this deal, NovaXS Biotech may no longer be accepting investments.

NovaXS Biotech Deal Report

Get KingsCrowd’s comprehensive report on NovaXS Biotech including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NovaXS Biotech is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the NovaXS Biotech deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge